SYK · Healthcare
STRYKER CORP
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Products and TechnologyImportance 48 · Surprise 64The global minimally invasive robotic surgical system market is projected to increase from $8.9 billion in 2025 to $18.15 billion by 2030, implying rapid expansion in demand for robotic-assisted surgery. Growth drivers…
- Supply Chain and Cybersecurity ImpactImportance 37 · Surprise 42Third-party reporting cited a cyberattack and supply-chain issues as operational disruptions affecting Stryker. The disruptions have contributed to investor concerns about execution and margin delivery despite reported…
- Manufacturing And CapacityImportance 37 · Surprise 42Stryker’s previously believed-resolved peripheral vascular manufacturing issue reportedly remains unresolved. The disclosure caused Stryker shares to fall $26.70, or 8.8%, on September 8, according to the third-party…
- Revenue Performance and MixImportance 36 · Surprise 14Stryker reported second-quarter 2026 revenue of $6.59 billion, up 9.4% year over year. The digest provides no segment or geographic revenue breakdown and therefore does not identify a mix shift. Operational disruptions…
News · 2026-09-22
- Product Launch and TransitionImportance 31 · Surprise 42At the 2026 AOFAS Annual Meeting, Stryker launched Prophecy Surgical Planning for its Incompass Total Ankle System. Stryker also introduced Hoffmann LRF smartHEX for limb reconstruction, adding digital and connectivity…
- Securities Fraud InvestigationImportance 25 · Surprise 42Pomerantz LLP announced on September 22, 2026 that it is investigating claims on behalf of Stryker investors. The investigation concerns potential securities-law violations, although the report does not specify the…
News · 2026-09-21
- Revenue Performance and MixImportance 36 · Surprise 14Stryker reported 9.4% revenue growth in the second quarter of 2026. The digest does not provide a segment or geographic revenue breakdown. The reported growth exceeds the 10% materiality threshold only marginally below…
- Operating Cash Flow TrendsImportance 36 · Surprise 6Stryker was described as having robust operating cash flow in connection with its second-quarter 2026 results. A separate report cited more than $4.1 billion in free cash flow, indicating substantial internally…
- Net Income and EPS PerformanceImportance 33 · Surprise 6Stryker reported $1.28 billion of net income for the second quarter of 2026. The digest does not provide diluted EPS, net margin, or the year-over-year change in net income. The reported net income is a material…
- Competition and Market PositionImportance 4 · Surprise 6Ambulatory Surgery Centers (ASCs) are identified as a growth market for robotic-surgery platforms. Intuitive Surgical is targeting ASCs with refurbished XiR models to provide lower-cost entry points into robotic…
News · 2026-09-18
- Revenue Performance and MixImportance 57 · Surprise 50Stryker reported quarterly revenue of $6.59 billion, up 9.4% year over year. Quarterly EPS was $3.69, exceeding the $3.49 analyst estimate. The company also issued optimistic fiscal 2026 EPS guidance, but the reported…
- Securities Fraud InvestigationImportance 31 · Surprise 42Block & Leviton is investigating Stryker Corporation for potential violations of U.S. securities laws. The investigation concerns investors who may have incurred losses in Stryker’s securities. The September 18, 2026…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Stryker declared a quarterly dividend of $0.88 per share. The dividend was cited alongside quarterly revenue of $6.59 billion and EPS of $3.69. The digest did not provide the dividend record date, payment date, or…
News · 2026-09-17
- Product Launch and TransitionImportance 31 · Surprise 42Stryker expanded its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX. The products connect surgical planning, implants and limb reconstruction. The launch strengthens Stryker’s integrated offering for…
- Manufacturing And CapacityImportance 26 · Surprise 24Canaccord Genuity cited ongoing manufacturing challenges in Stryker’s Peripheral Vascular unit. The report also identified unexpected seasonality in the Joint Replacement business as an operational headwind. These…
News · 2026-09-16
- Product Launch and TransitionImportance 31 · Surprise 42Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. The connected platform provides 3D visualization…
- Manufacturing And CapacityImportance 17 · Surprise 24Stryker’s CFO reportedly disclosed that a manufacturing issue previously believed to be resolved is still persisting. The issue relates to peripheral vascular products or operations, although the digest provides no…
News · 2026-09-15
- Securities Fraud InvestigationImportance 31 · Surprise 42Stryker is facing a legal investigation into potential securities-law violations. The probe concerns conflicting statements about a manufacturing issue. The reporting does not disclose the investigating authority,…
- Guidance / OutlookImportance 26 · Surprise 24Stryker maintained its fiscal 2026 guidance despite the legal probe. The report does not specify the revenue, margin, EPS, or capital-expenditure ranges covered by the guidance. Analysts continued to rate the company…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Stryker recently declared a quarterly dividend of $0.88 per share. The dividend declaration provides a recurring cash return to shareholders. The reported dividend was cited alongside Stryker’s reaffirmed fiscal 2026…
News · 2026-09-14
- Procedure Volume TrendsImportance 17 · Surprise 24Stryker is experiencing weaker orthopedic procedure volume growth, creating a demand headwind for its orthopaedics business. The company also faces a Vascular manufacturing issue that is constraining operational…
News · 2026-09-11
- Securities Fraud InvestigationImportance 25 · Surprise 42Block & Leviton announced on September 11, 2026, that it is investigating Stryker for potential violations of U.S. securities laws. The investigation concerns investors who lost money in Stryker investments, but the…
News · 2026-09-10
- Supply Chain and Cybersecurity ImpactImportance 40 · Surprise 42Stryker’s peripheral vascular business continues to face supply issues caused by a March cyberattack. The company had expected the disruptions to be resolved by the third quarter, but they may extend into the fourth…
- Market Demand TrendsImportance 20 · Surprise 24Stryker shares fell 9.7% after management reported unexpectedly slower hip sales. The weakness was attributed to a softer European market, seasonality, inflation, and higher insurance deductibles affecting U.S.…
News · 2026-09-09
- Guidance / OutlookImportance 51 · Surprise 60Stryker reportedly raised its full-year 2026 guidance after reporting second-quarter 2026 results that exceeded expectations. Wells Fargo subsequently reduced its 2026 revenue and EPS estimates below Stryker’s…
- Products and TechnologyImportance 31 · Surprise 42Stryker and Duke Health are implementing augmented reality in hip surgery using Apple Vision Pro. The technology is intended to enhance surgical precision and patient outcomes. The collaboration indicates potential…
- Strategic InitiativesImportance 31 · Surprise 42Duke Health and Stryker are implementing augmented-reality technology in hip surgery. The collaboration uses Apple Vision Pro to support surgical procedures. The reported objective is to enhance surgical precision and…
- Securities Fraud InvestigationImportance 25 · Surprise 42The Law Offices of Frank R. Cruz announced an investigation into Stryker concerning possible violations of U.S. federal securities laws. The investigation relates to Stryker’s reported second-quarter 2026 results…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Stryker declared a quarterly dividend of $0.88 per share. The dividend was reported on September 9, 2026, in coverage of the company’s recent quarterly results. The available report does not provide an ex-dividend…
News · 2026-09-08
- Guidance / OutlookImportance 51 · Surprise 60Third-party reporting states that Stryker raised its fiscal 2026 organic-growth and EPS guidance. The report also says Stryker had reaffirmed fiscal 2026 EPS guidance in connection with its second-quarter results. The…
- Supply Chain ConstraintsImportance 40 · Surprise 42A manufacturing problem that Stryker had previously said was addressed reportedly continued to persist. The issue was expected to extend into the fourth quarter, indicating a longer disruption than previously…
- Revenue Performance and MixImportance 35 · Surprise 14Stryker reported second-quarter 2026 revenue of $6.59 billion, up 9.4% year over year. The company exceeded earnings expectations with quarterly EPS of $3.69. Stryker reaffirmed its fiscal 2026 EPS guidance and…
- Securities Fraud InvestigationImportance 31 · Surprise 42Block & Leviton is investigating Stryker for potential securities-law violations after the company’s shares fell approximately 8%. The investigation follows disclosures that a manufacturing problem previously described…
News · 2026-09-07
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42Stryker is set to acquire ZuriMED and add the FiberLocker System to its shoulder portfolio. FiberLocker is intended to reinforce rotator-cuff repairs and has FDA clearance. The acquisition terms, revenue contribution,…
News · 2026-09-06
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42Stryker is set to acquire ZuriMED and add the FiberLocker System to its shoulder portfolio. FiberLocker is intended to reinforce rotator-cuff repairs and has FDA clearance. The acquisition terms, revenue contribution,…
- Securities Fraud InvestigationImportance 31 · Surprise 42Block & Leviton is investigating Stryker for potential securities-law violations after the company’s shares fell approximately 8%. The investigation follows disclosures that a manufacturing problem previously described…
News · 2026-09-05
- Revenue Performance and MixImportance 35 · Surprise 14Stryker reported second-quarter 2026 revenue of $6.59 billion, up 9.4% year over year. The company exceeded earnings expectations with quarterly EPS of $3.69. Stryker reaffirmed its fiscal 2026 EPS guidance and…
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42Stryker is set to acquire ZuriMED and add the FiberLocker System to its shoulder portfolio. FiberLocker is intended to reinforce rotator-cuff repairs and has FDA clearance. The acquisition terms, revenue contribution,…
- Regulatory Approval MilestonesImportance 31 · Surprise 42Stryker launched SportSuite Vision, an FDA-cleared application for Apple Vision Pro. The application is designed for use in hip arthroscopy. The launch supports Stryker’s digital-surgery strategy and expands its Sports…
- Quarterly Dividend DeclarationImportance 6 · Surprise 6Stryker declared a quarterly dividend of $0.88 per share. The dividend implies an annualized yield of approximately 1.2% based on the cited market price. The digest did not report a dividend increase, payment date, or…
News · 2026-09-04
- Guidance / OutlookImportance 51 · Surprise 60Third-party reporting states that Stryker raised its fiscal 2026 organic-growth and EPS guidance. The report also says Stryker had reaffirmed fiscal 2026 EPS guidance in connection with its second-quarter results. The…
News · 2026-09-03
- Guidance / OutlookImportance 51 · Surprise 60Third-party reporting states that Stryker raised its fiscal 2026 organic-growth and EPS guidance. The report also says Stryker had reaffirmed fiscal 2026 EPS guidance in connection with its second-quarter results. The…
- Revenue Performance and MixImportance 35 · Surprise 14Stryker reported second-quarter 2026 revenue of $6.59 billion, up 9.4% year over year. The company exceeded earnings expectations with quarterly EPS of $3.69. Stryker reaffirmed its fiscal 2026 EPS guidance and…
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42Stryker is set to acquire ZuriMED and add the FiberLocker System to its shoulder portfolio. FiberLocker is intended to reinforce rotator-cuff repairs and has FDA clearance. The acquisition terms, revenue contribution,…
- Regulatory Approval MilestonesImportance 31 · Surprise 42Stryker launched SportSuite Vision, an FDA-cleared application for Apple Vision Pro. The application is designed for use in hip arthroscopy. The launch supports Stryker’s digital-surgery strategy and expands its Sports…
News · 2026-09-01
- Products and TechnologyImportance 38 · Surprise 60Stryker completed the first hip arthroscopy using SportSuite Vision on Apple Vision Pro at a leading academic medical center on September 1, 2026. The application provides surgeons with access to critical clinical…
- Acquisition / Partnership / DivestitureImportance 38 · Surprise 60Stryker plans to acquire ZuriMED to expand its shoulder-care portfolio. The transaction would add ZuriMED’s FiberLocker System and strengthen Stryker’s rotator-cuff care capabilities. The third-party report does not…
- Product Launch and TransitionImportance 38 · Surprise 60Stryker completed the first reported hip arthroscopy procedure using SportSuite Vision on Apple Vision Pro at a leading academic medical center. SportSuite Vision provides surgeons with access to critical clinical…
- Regulatory Approval MilestonesImportance 38 · Surprise 60Stryker received FDA De Novo authorization for SportSuite Vision, an intraoperative surgical application for Apple Vision Pro. The authorization covers use of the spatial-computing application during surgery, including…
News · 2026-08-31
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42Stryker partnered with the Indian Association of Gynaecological Endoscopists (IAGE) to advance surgeon education in fluorescence-guided surgery for gynaecology in India. The collaboration will provide clinical…
- Licensing / Collaboration DealsImportance 31 · Surprise 42Stryker partnered with the Indian Association of Gynaecological Endoscopists (IAGE) to advance surgeon education in fluorescence-guided surgery (FGS) for gynaecology in India. The collaboration will provide pan-India…
News · 2026-08-26
- Revenue Performance and MixImportance 42 · Surprise 14Stryker reported second-quarter 2026 revenue of $6.59 billion, representing 9% year-over-year growth. The digest does not provide revenue by operating segment, product category, or geography. Quarterly earnings…
- Guidance / OutlookImportance 36 · Surprise 24Stryker maintained its full-year 2026 adjusted EPS guidance range of $14.95 to $15.10. The guidance remained intact despite supply-chain and operational challenges cited after the second-quarter earnings release. The…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Stryker declared a quarterly dividend of $0.88 per share. The dividend was reported alongside second-quarter 2026 revenue of $6.59 billion and EPS of $3.69. The digest does not state the record date, payment date, or…
- Net Income and EPS PerformanceImportance 9 · Surprise 6Stryker reported second-quarter 2026 EPS of $3.69. The company exceeded analyst estimates for quarterly earnings. The digest does not disclose net income, diluted share count, or the year-over-year EPS change.
News · 2026-08-25
- Revenue Performance and MixImportance 33 · Surprise 6Stryker reported quarterly revenue of $6.59 billion. Quarterly revenue exceeded analyst expectations, according to third-party reporting. The digest did not provide YoY or sequential revenue growth, segment revenue, or…
- Guidance / OutlookImportance 26 · Surprise 24Stryker maintained fiscal 2026 diluted EPS guidance of $14.95 to $15.10. The guidance was reiterated following quarterly revenue of $6.59 billion and EPS of $3.69, although those historical performance metrics are not…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Stryker declared a quarterly dividend of $0.88 per share. The reported dividend implies approximately $3.52 per share on an annualized basis if maintained for four quarters. The digest also cited a dividend yield of…
- Net Income and EPS PerformanceImportance 9 · Surprise 6Stryker reported quarterly EPS of $3.69. The reported EPS exceeded analyst expectations. The digest did not provide quarterly net income, YoY EPS growth, or sequential EPS change.
News · 2026-08-24
- Revenue Performance and MixImportance 33 · Surprise 6Stryker reported quarterly revenue of $6.59 billion. Quarterly earnings were $3.69 per share, exceeding analyst expectations. The digest provides no year-over-year, sequential, or segment revenue breakdown for the…